Automated Author ProfileParkes, Joanna E.
Parkes, Joanna E.
Current S-Index
Sum of Dataset Indices for all datasets
Average Dataset Index per Dataset
Average Dataset Index per dataset
Total Datasets
Total datasets for this author
Average FAIR Score
Average FAIR Score per dataset
Total Citations
Total citations to the author's datasets
Total Mentions
Total mentions of the author's datasets
S-Index Interpretation
The S-Index (Sharing Index) is a comprehensive metric that represents the cumulative impact of all your datasets. It is calculated as the sum of Dataset Index scores across all your claimed datasets.
What it means:
- A higher S-index indicates greater overall impact of your datasets relative to typical datasets in their fields of research
- The S-Index grows as you add more datasets or as existing datasets gain more citations and mentions
- It provides a single number to track your research data impact over time
Current S-Index: 5.6 (sum of 8 datasets Dataset Index scores)
More information here.
S-Index Over Time
Cumulative Citations Over Time
Cumulative Mentions Over Time
Datasets
Additional file 2 Significant RNA sequencing differential expression in polymyositis, dermatomyositis and inclusion body myositis patients versus controls PM Polymyositis, DM Dermatomyositis, IBM Inclusion body myositis, Anti-Jo1 Subset of PM and DM with anti-Jo1 autoantibodies Data generated by DESeq2 analysis of RNA sequencing data from 7 PM, 7 DM, 5 IBM compared to 5 control whole blood samples. The table columns are gene ids, log2 fold change, standard error for log2 fold change (lfcSE), statistic value for the null hypothesis (stat), p-value, false discovery rate (padj), and gene name.
Authors
- Parkes, Joanna E. ;
- Thoma, Anastasia ;
- Lightfoot, Adam P. ;
- Day, Philip J. ;
- Chinoy, Hector ;
- Lamb, Janine A.
Additional file 2 Significant RNA sequencing differential expression in polymyositis, dermatomyositis and inclusion body myositis patients versus controls PM Polymyositis, DM Dermatomyositis, IBM Inclusion body myositis, Anti-Jo1 Subset of PM and DM with anti-Jo1 autoantibodies Data generated by DESeq2 analysis of RNA sequencing data from 7 PM, 7 DM, 5 IBM compared to 5 control whole blood samples. The table columns are gene ids, log2 fold change, standard error for log2 fold change (lfcSE), statistic value for the null hypothesis (stat), p-value, false discovery rate (padj), and gene name.
Authors
- Parkes, Joanna E. ;
- Thoma, Anastasia ;
- Lightfoot, Adam P. ;
- Day, Philip J. ;
- Chinoy, Hector ;
- Lamb, Janine A.
Additional file 3 Significant microRNA sequencing differential expression in polymyositis, dermatomyositis and inclusion body myositis patients versus controls PM Polymyositis, DM Dermatomyositis, IBM Inclusion body myositis, Anti-Jo1 Subset of PM and DM with anti-Jo1 autoantibodies Data generated by DESeq2 analysis of small RNA sequencing data from 7 PM, 7 DM, 5 IBM compared to 5 control whole blood samples. The table columns are mature microRNA ids, log2 fold change, standard error for log2 fold change (lfcSE), statistic value for the null hypothesis (stat), p-value, false discovery rate (padj), and mature microRNA name.
Authors
- Parkes, Joanna E. ;
- Thoma, Anastasia ;
- Lightfoot, Adam P. ;
- Day, Philip J. ;
- Chinoy, Hector ;
- Lamb, Janine A.
Additional file 3 Significant microRNA sequencing differential expression in polymyositis, dermatomyositis and inclusion body myositis patients versus controls PM Polymyositis, DM Dermatomyositis, IBM Inclusion body myositis, Anti-Jo1 Subset of PM and DM with anti-Jo1 autoantibodies Data generated by DESeq2 analysis of small RNA sequencing data from 7 PM, 7 DM, 5 IBM compared to 5 control whole blood samples. The table columns are mature microRNA ids, log2 fold change, standard error for log2 fold change (lfcSE), statistic value for the null hypothesis (stat), p-value, false discovery rate (padj), and mature microRNA name.
Authors
- Parkes, Joanna E. ;
- Thoma, Anastasia ;
- Lightfoot, Adam P. ;
- Day, Philip J. ;
- Chinoy, Hector ;
- Lamb, Janine A.
Additional file 4 GOseq analysis of differentially expressed genes in idiopathic inflammatory myopathy patients versus controls PM Polymyositis, DM Dermatomyositis, IBM Inclusion body myositis, Anti-Jo1 Subset of PM and DM with anti-Jo1 autoantibodies GOseq analysis was performed on significantly differentially expressed genes (FDR
Authors
- Parkes, Joanna E. ;
- Thoma, Anastasia ;
- Lightfoot, Adam P. ;
- Day, Philip J. ;
- Chinoy, Hector ;
- Lamb, Janine A.
Additional file 4 GOseq analysis of differentially expressed genes in idiopathic inflammatory myopathy patients versus controls PM Polymyositis, DM Dermatomyositis, IBM Inclusion body myositis, Anti-Jo1 Subset of PM and DM with anti-Jo1 autoantibodies GOseq analysis was performed on significantly differentially expressed genes (FDR
Authors
- Parkes, Joanna E. ;
- Thoma, Anastasia ;
- Lightfoot, Adam P. ;
- Day, Philip J. ;
- Chinoy, Hector ;
- Lamb, Janine A.
Additional file 5 Canonical Pathways with an enrichment of significantly differentially expressed genes in idiopathic inflammatory myopathy patients PM Polymyositis, DM Dermatomyositis, IBM Inclusion body myositis, Anti-Jo1 Subset of PM and DM with anti-Jo1 autoantibodies QIAGEN’s Ingenuity Pathway Analysis (IPA) ‘Canonical Pathways’ analysis was performed on differential expression results from RNA sequencing of 7 PM and 7 DM (5 anti-Jo1 autoantibody positive), 5 IBM and 5 control whole blood samples. Columns are IPA defined canonical pathway, −log(p-value) for over-representation of dysregulated molecules in the pathway (> 1.3 is considered significant), ratio of dysregulated molecules to total molecules in pathway, activation score (z-score > 2 is significant predicted activation,
Authors
- Parkes, Joanna E. ;
- Thoma, Anastasia ;
- Lightfoot, Adam P. ;
- Day, Philip J. ;
- Chinoy, Hector ;
- Lamb, Janine A.
Additional file 5 Canonical Pathways with an enrichment of significantly differentially expressed genes in idiopathic inflammatory myopathy patients PM Polymyositis, DM Dermatomyositis, IBM Inclusion body myositis, Anti-Jo1 Subset of PM and DM with anti-Jo1 autoantibodies QIAGEN’s Ingenuity Pathway Analysis (IPA) ‘Canonical Pathways’ analysis was performed on differential expression results from RNA sequencing of 7 PM and 7 DM (5 anti-Jo1 autoantibody positive), 5 IBM and 5 control whole blood samples. Columns are IPA defined canonical pathway, −log(p-value) for over-representation of dysregulated molecules in the pathway (> 1.3 is considered significant), ratio of dysregulated molecules to total molecules in pathway, activation score (z-score > 2 is significant predicted activation,
Authors
- Parkes, Joanna E. ;
- Thoma, Anastasia ;
- Lightfoot, Adam P. ;
- Day, Philip J. ;
- Chinoy, Hector ;
- Lamb, Janine A.